A practical reference on tesamorelin: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-05-23 and is reviewed periodically as new material appears.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | N-terminal trans-3-hexenoyl group |
| Approximate mass | About 5.1 kDa | Derived from the peptide sequence |
| Primary target | Pituitary GHRH receptor | Somatotroph cells of the anterior pituitary |
| Downstream marker | IGF-1 | Measured indirectly in circulation |
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
In the West, the glass is normally a borosilicate glass (similar to Pyrex), while in the former Soviet Union it is normal to use a phosphate glass. The amount of fission products in the glass must be limited because some (palladium, the other Pt group metals, and tellurium) tend to form metallic phases which separate from the glass. Bulk vitrification uses electrodes to melt soil and wastes, which are then buried underground. In Germany, a vitrification plant is treating the waste from a small demonstration reprocessing plant which has since been closed.
Donislecel, sold under the brand name Lantidra, is a cellular therapy medication used for the treatment of type 1 diabetes. Donislecel is an allogeneic (donor) pancreatic islet cellular therapy made from deceased donor pancreatic cells. Donislecel is administered as a single infusion into the hepatic (liver) portal vein. The most common adverse reactions include nausea, fatigue, anemia, diarrhea, and abdominal pain. Donislecel was approved for medical use in the United States in June 2023.
Recombinant myoglobin for faux meat (Motif Foodworks) Recombinant leghemoglobin for faux meat (Impossible Foods) Recombinant whey protein for dairy replacement (Perfect Day) Recombinant casein protein for dairy replacements (Those Vegan Cowboys) Recombinant egg white (EVERY) Heme proteins such as myoglobin and hemoglobin give meat its characteristic texture, flavor, color, and aroma. The myoglobin and leghemoglobin ingredients can be used to replicate this property, despite them coming from a vat instead of meat.
=== 2014 === On January 22, 2014, European Southern Observatory became the first scientific organization to deliver Ultra HD footage at regular intervals. On May 6, 2014, France announced DVB-T2 tests in Paris for Ultra HD HEVC broadcast with objectives to replace by 2020 the current DVB-T MPEG4 HD national broadcast. On May 26, 2014, satellite operator Eutelsat announced the launch of Europe's first Ultra HD demo channel in HEVC, broadcasting at 50 fps. The channel is available on the Hot Bird satellites and can be watched by viewers with 4K TVs equipped with DVB-S2 demodulators and HEVC decoders. In June 2014, the FIFA World Cup of that year (held in Brazil) became the first shot entirely in 4K Ultra HD, by Sony. The European Broadcasting Union (EBU) broadcast matches of the FIFA World Cup to audiences in North America, Latin America, Europe and Asia in Ultra HD via SES' NSS-7 and SES-6 satellites. Indian satellite TV provider unveils its plan to launch 4K UHD service early in 2015 and showcased live FIFA World Cup quarter final match in 4K UHD through Sony Entertainment Television Sony SIX. On June 24, 2014, the CEA updated the guidelines for Ultra High-Definition and released guidelines for Connected Ultra High-Definition, adding support for internet video delivered with HEVC. The CEA is developing a UHD logo for voluntary use by companies that make products that meet CEA guidelines. The CEA also clarified that "Ultra High-Definition", "Ultra HD", or "UHD" can be used with other modifiers and gave an example with "Ultra High-Definition TV 4K".
Sources: en.wikipedia.org
== High-school student teaching with AIDA on-line == The lifetime risk of developing diabetes for students born since the year 2000 in the United States is estimated to be 27% to 52%. Many students need to learn about diabetes for their personal care, or for the care of relatives, or desire to learn about diabetes to develop a career in healthcare. Most teenagers are adept at learning through web-based computer tools. Against this background, 21 students entering the 8th and 9th grades (aged 12 to 14 years old) enrolled in a Biotechnology Summer Camp in June 2006 — organized independently by the Georgia Institute of Technology in Atlanta, Georgia (USA) — focusing on diabetes mellitus. Lectures on pathophysiology and clinical aspects of diabetes were followed by simulated cases using the AIDA on-line diabetes software simulator. Two cases demonstrated glycemic effects and pharmacokinetics of insulin administration, diet, and exercise in insulin-dependent type 1 diabetes mellitus and non-insulin-dependent type 2 diabetes mellitus. Students filled out standardized evaluations at the end of the session to assess receptiveness to this type of learning; opinions on the utility, information, and ease of use; and perceived risks of using the on-line simulator to understand diabetes. All students were receptive to this simulator-based educational approach.
=== EC 1.21.98 With other, known, physiological acceptors === EC 1.21.98.1: cyclic dehypoxanthinyl futalosine synthase EC 1.21.98.2: dichlorochromopyrrolate synthase EC 1.21.98.3: anaerobic magnesium-protoporphyrin IX monomethyl ester cyclase EC 1.21.98.4: PqqA peptide cyclase
== Reporting of yields == In their 2010 Synlett article, Martina Wernerova and organic chemist, Tomáš Hudlický, raised concerns about inaccurate reporting of yields, and offered solutions—including the proper characterization of compounds. After performing careful control experiments, Wernerova and Hudlický said that each physical manipulation (including extraction/washing, drying over desiccant, filtration, and column chromatography) results in a loss of yield of about 2%. Thus, isolated yields measured after standard aqueous workup and chromatographic purification should seldom exceed 94%. They called this phenomenon "yield inflation" and said that yield inflation had gradually crept upward in recent decades in chemistry literature. They attributed yield inflation to careless measurement of yield on reactions conducted on small scale, wishful thinking and a desire to report higher numbers for publication purposes.
Windtree Therapeutics, Inc. (formerly Discovery Laboratories) is an American company which was set up in 1992 and now is based in Warrington, Pennsylvania, developing drug products (pulmonary medicine) for patients with respiratory disease. The company joined an alliance with Laboratorios del Dr. Esteve, S.A. In 2016, Discovery Laboratories changed name to Windtree Therapeutics, Inc.
=== Glutaminolysis and transamination === Aside from the citric acid cycle, α-ketoglutarate is made by glutaminolysis in which the enzyme glutaminase removes the amino group from glutamine to form glutamate which is converted to α-ketoglutarate by any one of three enzymes, glutamate dehydrogenase, alanine transaminase, or aspartate transaminase (see The glutaminolytic pathways). It is also made through the action of pyridoxal phosphate-dependent enzymes (alanine transaminase) in which glutamate is converted to α-Ketoglutarate by "donating" its −NH2 to other compounds (see transamination). These reactions are reversible. In the reverse direction of these reactions, α-ketoglutarate contributes to the production of amino acids such as glutamine, proline, arginine, and lysine as well as the lowering of cellular carbon and nitrogen (i.e., N) levels; this prevents excessive levels of these two potentially toxic elements from accumulating in cells and tissues. The neurotoxin, ammonia (i.e., NH3), is also prevented from accumulating in tissues. In this metabolic pathway the −NH2 group on an amino acid is transferred to α-ketoglutarate; this forms the α-keto acid of the original amino acid and the amine-containing product of α-ketoglutarate, glutamate. The cellular glutamate passes into the circulation and is taken up by the liver where it delivers its acquired −NH2 group to the urea cycle. In effect, the latter pathway removes excess ammonia from the body in the form of urinary urea.
Sources: en.wikipedia.org
==== 3100–3199 ==== Credit Unions (Authorised Investments) Order 1993 (S.I. 1993/3100) Education (Schools Conducted by Education Associations) (Initial Articles of Government) Regulations 1993 (S.I. 1993/3101) Education (Grant-maintained Schools) (Initial Governing Instruments) Regulations 1993 (S.I. 1993/3102) Education (Schools Conducted by Education Associations) Regulations 1993 (S.I. 1993/3103) Education (Application of Financing Schemes to Special Schools) Regulations 1993 (S.I. 1993/3104) Education (School Curriculum and Assessment Authority) (Orders for Transfer of Property and Staff) Order 1993 (S.I. 1993/3105) Education Act 1993 (Commencement No. 2 and Transitional Provisions) Order 1993 (S.I. 1993/3106) Education (School Government) (Amendment) Regulations 1993 (S.I. 1993/3107) Local Government (Compensation for Premature Retirement) (Amendment) (No. 2) Regulations 1993 (S.I. 1993/3108) Insurance Companies (Pension Business) (Transitional Provisions) (Amendment) Regulations 1993 (S.I. 1993/3109) Stamp Duty Reserve Tax (Amendment) Regulations 1993 (S.I. 1993/3110) Friendly Societies (Modification of the Corporation Tax Acts) (Amendment) Regulations 1993 (S.I. 1993/3111) Friendly Societies (Provisional Repayments for Exempt Business) Regulations 1993 (S.I. 1993/3112) Education (Publication of School Proposals and Notices) Regulations 1993 (S.I. 1993/3113) Education Assets Board (Transfers under the Education Reform Act 1988) (Amendment) Regulations 1993 (S.I.
Harrington, William J.; Sprague, Charles C.; Minnich, Virginia; Moore, Carl V.; Aulvin, Robert C.; Dubach, Reubenia (1953-03-01). "Immunologic mechanisms in idiopathic and neonatal thrombocytopenic purpura". Annals of Internal Medicine. 38 (3): 433–69. doi:10.7326/0003-4819-38-3-433. ISSN 0003-4819. PMID 13031392. Hemoglobin E
=== Short-term effects === Insufflating (snorting) cocaine commonly causes increased mucus production due to irritation and inflammation of the nasal passages. This irritation leads to symptoms such as a runny nose, nasal congestion, and excessive or thickened mucus. Acute exposure to cocaine has many effects on humans, including euphoria, increases in heart rate and blood pressure, and increases in cortisol secretion from the adrenal gland. In humans with acute exposure followed by continuous exposure to cocaine at a constant blood concentration, the acute tolerance to the chronotropic cardiac effects of cocaine begins after about 10 minutes, while acute tolerance to the euphoric effects of cocaine begins after about one hour. With excessive or prolonged use, the drug can cause itching, fast heart rate, and paranoid delusions or sensations of insects crawling on the skin. Cocaine can induce psychosis characterized by paranoia, impaired reality testing, hallucinations, irritability, and physical aggression. Cocaine intoxication can cause hyperawareness, hypervigilance, psychomotor agitation, and delirium. Consumption of large doses of cocaine can cause violent outbursts, especially by those with preexisting psychosis. Acute exposure may induce arrhythmia, including atrial fibrillation, supraventricular tachycardia, ventricular tachycardia, and ventricular fibrillation. Acute exposure may also lead to angina, heart attack, and congestive heart failure.
If it were not for the accidental negroes [brought by Treasurer], I were not able to raise one pound of tobacco this year for the defrayment of any public work….These slaves are the most proper and cheap instruments for this plantation that can be. Soil degradation also resulted and continues to result from tobacco growing in general and through tobacco monocropping/monoculture specifically.
=== Sub-Saharan Africa === In Sub-Saharan Africa, the food distribution crisis of the 1970s and 1980s was a result of a multitude of food distribution risk factors including political problems, economic failures, and weather conditions. The heart of the political problems and economic failures affecting food distribution included poor agricultural pricing and a lack of state involvement with rural development. Some of the political problems can be traced back to the colonial period. Colonial policy supported the exportation of goods, even if it meant decreasing the amount of food for the local economy. Components of these colonial policies continued to be used after African countries gained their freedom from European nations. The usage of these failed policies caused malignant consequences on the economic situation of the peasant class, including the exploitation of peasant agriculture and in removal of peasants from their land. The weather and environmental issues regarding the Sub-Saharan African food distribution crisis also have roots in failed colonial policy. Labor migration cycles used during colonial times were ecologically damaging to the local environment and failed to create new areas for growing crops. As a result, desertification and a loss of soil fertility hurt the local agricultural sector, which then in turn negatively affected food distribution. The world's farmers produce enough food to feed 12 billion people, but the inequal food distribution leaves hundreds of millions hungry.
Sources: en.wikipedia.org
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.
The N-terminal modification reduces cleavage by circulating peptidases, so the peptide persists longer than native GHRH. That persistence is the main rationale for the synthetic design. Comparative half-life values in humans are reported in regulatory review documents rather than in general reference literature.
Reductions in visceral adipose tissue have been measured in controlled studies of defined populations. Whether the effect generalizes to other groups and persists after treatment stops is less clear. Longer-term outcome data remain limited.
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.